论文部分内容阅读
目的观察门冬胰岛素治疗2型糖尿病的临床疗效及安全性。方法选择2009年1月至2009年6月本院内分泌病区收治的T2DM患者80例,随机分为两组,治疗组40例,对照组40例。治疗组给予门冬胰岛素(诺和锐)皮下注射治疗,对照组以诺和灵R皮下注射治疗,取这10周空腹血糖及餐后2h血糖作为临床观察指标,治疗结束时测糖化血红蛋白(HbA1c)。结果治疗组组内空腹血糖、餐后2h血糖以及HbAlc治疗前后比较差异有明显统计学意义(P<0.01);对照组组内空腹血糖、餐后2h血糖以及HbAlc治疗前后比较,差异有明显统计学意义(P<0.01);治疗组治疗后空腹血糖、餐后2h血糖以及HbAlc明显低于对照组(P<0.01),低血糖发生率明显低于对照组(P<0.01)。结论门冬胰岛素能更好的降低血糖、糖化血红蛋白及低血糖发生率。
Objective To observe the clinical efficacy and safety of insulin aspart as treatment for type 2 diabetes mellitus. Methods 80 patients with T2DM admitted to our hospital from January 2009 to June 2009 were randomly divided into two groups: treatment group (40 cases) and control group (40 cases). The treatment group was treated with insulin aspart (Nuoherui) subcutaneously, while the control group was treated with Nuoheling R subcutaneously. The fasting blood glucose and 2-hour postprandial blood glucose were taken as the clinical observation indicators. After the treatment, HbA1c ). Results The fasting blood glucose, 2h postprandial blood glucose and the difference of HbAlc before and after treatment in the treatment group were significantly different (P <0.01). The fasting blood glucose, 2h postprandial blood glucose and HbAlc before and after treatment were significantly different (P <0.01). After treatment, the fasting blood glucose, postprandial 2h blood glucose and HbAlc in the treatment group were significantly lower than those in the control group (P <0.01). The incidence of hypoglycemia in the treatment group was significantly lower than that in the control group (P <0.01). Conclusion Aspart insulin can lower blood glucose, glycosylated hemoglobin and incidence of hypoglycemia.